MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
18.80
+0.05 (0.27%)
Aug 14, 2025, 11:45 AM - Market open
Company Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally.
It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.
MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd.
| Country | Israel |
| Founded | 2000 |
| IPO Date | Mar 20, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Ofer Gonen |
Contact Details
Address: 42 Hayarkon Street Yavne, 8122745 Israel | |
| Phone | 972 7 797 14100 |
| Website | mediwound.com |
Stock Details
| Ticker Symbol | MDWD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001593984 |
| CUSIP Number | M68830104 |
| ISIN Number | IL0011316309 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Ofer Gonen B.Sc. | Chief Executive Officer |
| Hani Luxenburg | Chief Financial Officer |
| Dr. Shmulik Hess Ph.D. | Chief Operating Officer and Chief Commercial Officer |
| Yaron Meyer Adv. | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. Ety Klinger MBA, Ph.D. | Chief Research and Development Officer |
| Barry J. Wolfenson | Executive Vice President of Strategy and Corporate Development |
| Hagit Mashiach | Vice President of Human Resources |
| Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | 6-K | Report of foreign issuer |
| Aug 12, 2025 | SCHEDULE 13G/A | Filing |
| May 21, 2025 | 6-K | Report of foreign issuer |
| May 15, 2025 | 6-K | Report of foreign issuer |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| Apr 7, 2025 | 6-K | Report of foreign issuer |
| Mar 28, 2025 | 424B3 | Prospectus |
| Mar 27, 2025 | EFFECT | Notice of Effectiveness |
| Mar 24, 2025 | UPLOAD | Filing |
| Mar 19, 2025 | F-3 | Filing |